Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Exploring the therapeutic potential of silkworm pupae extract and stromal vascular fraction in diabetic wound healing.

Khosropanah MH., Hassannejad Z., Azimzadeh A., Tanourlouee SB., Ghofrani A., Mohebbi A.

Animal Study on Diabetic Foot, Chronic Wound, Chronic Inflammation, published in Tissue Cell (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Tissue Cell (2025)
Country
Scotland
Reported sample size
—
Source database
PubMed
PMID
41353903
DOI
10.1016/j.tice.2025.103231
Citations
1

Abstract (original English)

Chronic wounds from diabetes mellitus (DM), a global health issue, may be healed by silkworm cocoon extract's antibacterial, anti-inflammatory, and antioxidant capabilities. Silkworm pupae extract was characterized based on the concentration and type of amino acids and proteins through Bradford assay, SDS-PAGE, and LC-MS/MS. For diabetic rat wound treatment, the extract was incorporated into silk fibroin/chitosan/hydrogel. Histology, immunohistochemistry, inflammation, neovascularization, and epidermal thickness were measured using ImageJ software over 3, 7, 14, and 21 days with or without stromal vascular fraction (SVF) cells to assess regeneration potential. On day 14, pupae extract and SVF cell hydrogels reduced inflammation. Both components reduced inflammation on day 7, however by day 14 there was insignificant difference from the control group. Neovascularization increased with pupae extract or a combination at days 3 and 7, but not 14 and 21. Epidermal thickness increased on days 7 and 14, whereas pupae extract and SVF cell collagen deposition peaked on days 14 and 21. We observed treatment effects on days 7 and 14, observing collagen deposition on days 14 and 21 (p < 0.01). While SVF group alone had less significant outcomes, the pupae extract with the SVF group responded most therapeutically, followed by the other group.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsWound HealingBombyxPupaRatsDiabetes Mellitus, ExperimentalStromal CellsMaleHydrogelsNeovascularization, Physiologic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research